Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 13

Lack of association between airflow limitation and recurrence of venous thromboembolism among cancer patients with pulmonary embolism

Authors Shin SH, Kang D, Cho J, Chang H, Kim MS, Lee SY, Lee H, Kim H, Kim DK, Kim EK, Park HY

Received 5 November 2017

Accepted for publication 8 February 2018

Published 20 March 2018 Volume 2018:13 Pages 937—943


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Richard Russell

Sun Hye Shin,1 Danbee Kang,2 Juhee Cho,2 Haseong Chang,Min Sun Kim,3 Su Yeon Lee,3 Hyun Lee,1 Hojoong Kim,1 Duk-Kyung Kim,3 Eun Kyoung Kim,3,* Hye Yun Park1,*

1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; 2Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea; 3Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

*These authors contributed equally to this work

Background: COPD is a well-known risk factor for venous thromboembolism (VTE) development. However, recent data showed that it was not associated with VTE recurrence risk, which excluded cancer patients. This study investigated the association of airflow limitation and VTE recurrence in cancer patients with pulmonary embolism (PE).
Methods: This is a retrospective cohort study of cancer patients with newly diagnosed PE at a university hospital. PE was confirmed using contrast-enhanced computed tomography scan. Airflow limitation was defined as pre-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) <0.7 within 2 years of PE diagnosis. VTE recurrence was defined as a composite of recurrence as PE or deep vein thrombosis or both.
Results: Among 401 cancer patients with newly diagnosed PE, spirometry-based airflow limitation was observed in 126 (31.4%) patients. Half of the patients had lung cancer, which was more common in the group with airflow limitation (65.1% vs 42.9%, p < 0.001). Symptomatic PE was present in less than half (45.4%) of the cases, and 62.6% of patients were treated for PE. During the median follow-up period of 9.7 months, VTE recurred in 49 (12.2%) patients. Compared with patients without airflow limitation, those with airflow limitation did not have an increased risk of VTE recurrence in univariate or multivariate analyses (adjusted hazard ratio, 1.29 [95% CI 0.68, 2.45]).
Conclusion: The presence of airflow limitation did not increase the risk of VTE recurrence in cancer patients with PE. Prospective studies are needed to validate this finding.

Keywords: chronic obstructive pulmonary disease, cancer, pulmonary embolism, recurrence, venous thromboembolism

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]